BioSpace News Archive

Aileron Therapeutics, a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, announced that it will effect a 1-for-20 reverse stock split of its common stock.

SOTIO Biotech presented preclinical dataevaluating the mechanism of action and metabolic function of its BOXR T cell platform in a poster presentation at the Society for Immunotherapy of Cancer 37th Annual Meeting, taking place in Boston, Massachusetts from November 8-12, 2022.

ProPhase Labs, Inc., a growth oriented and diversified diagnostics, genomics and biotech company, reported its financial and operational results for the third quarter ended September 30, 2022.

Prenetics Global Limited, a global leader in genomic and diagnostic testing, announced its unaudited financial results for the third quarter ended September 30, 2022.

Landos Biopharma, Inc., a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, announced financial results for the third quarter ended September 30, 2022, and provided a business update.

Galvanize Therapeutics, Inc. announced promising clinical data using its Aliya™ Pulsed Electric Field system in patients with non-small cell lung cancer.

KaliVir Immunotherapeutics, Inc. announced the presentation of data on its lead pre-clinical candidate VET3-TGI presented in a poster session at the 37th Annual Meeting of the Society for Immunology of Cancer in Boston, Massachusetts.

Alpheus™ Medical, Inc, a privately held company developing a novel sonodynamic therapy (SDT) platform targeting solid body cancers, today announced the treatment of the first three patients in the U.S.-based multi-center Phase 1 clinical trial evaluating the safety and optimal dosage of the company’s proprietary platform.

Wugen, Inc. today announced that management will present at 9:45 a.m. GMT (4:45 a.m. ET) on Thursday, November 17, 2022 at the upcoming Jefferies London Healthcare Conference.

Corner Therapeutics debuts today with presentation of data on its dendritic cell hyperactivation (hDC) platform at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place November 8-12, 2022 in Boston, Massachusetts.